Patients with type 2 diabetes and established CVD are at very high risk for major adverse cardiovascular events. For patients with type 2 diabetes and ASCVD who require additional lowering of LDL cholesterol despite the maximally tolerated dose of statins and cholesterol absorption inhibitor, such as ezetimibe, the American College of Cardiology and European Society of Cardiology recommend the addition of a PCSK9 inhibitor. These recommendations were made after the FOURIER clinical trial demonstrated that patients taking evolocumab were at a significantly lower risk compared with placebo for cardiovascular events: stroke, myocardial infarction, and coronary revascularization. In addition, evolocumab was shown to reduce cholesterol by 59%.
Icosapent ethyl may be an option to lower triglycerides in patients being treated with statin therapy. In randomized trials, icosapent ethyl was demonstrated to improve the risk for subsequent ischemic events in patients with a history of prior percutaneous coronary intervention.
Learn more about type 2 diabetes.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters, Romesh Khardori. Fast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape - Apr 21, 2023.